Caroline McSween, PA
Physician Assistant · Newport, TNNPI 1891190617
Payments from drug & device makers
Across 164 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$762
- GSK$317
- Novo Nordisk$298
- AstraZeneca$177
- Pfizer$147
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$145
- plus $760 from 17 others
What the payments were for
- Food & beverage$2,606100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $762 |
| GSK | 20 | $317 |
| Novo Nordisk | 29 | $298 |
| AstraZeneca | 12 | $177 |
| Pfizer | 10 | $147 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $145 |
| Lilly USA, LLC | 7 | $121 |
| Amgen | 6 | $88 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $84 |
| Phathom Pharmaceuticals, Inc. | 4 | $76 |
| Astellas Pharma US Inc | 2 | $50 |
| Boehringer Ingelheim | 3 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Corcept Therapeutics | 2 | $37 |
| Bayer | 2 | $37 |
| Convatec Inc. | 1 | $27 |
| Dexcom, Inc. | 1 | $27 |
| Baxter Healthcare | 1 | $25 |
| Abbott | 1 | $25 |
| Shield Therapeutics Inc | 1 | $24 |
| Alkermes, Inc. | 1 | $22 |
| Merck | 1 | $15 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$125
How this compares
$2,606 in reported general payments places this provider in the 80th percentile of 2,404 physician assistant providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 97 | $83,161 |
| OzempicSemaglutide | 54 | $73,743 |
| MounjaroTirzepatide | 45 | $44,765 |
| JardianceEmpagliflozin | 39 | $33,312 |
| EliquisApixaban | 22 | $21,155 |
| TrulicityDulaglutide | 18 | $19,468 |
| VraylarCariprazine Hcl | 12 | $17,454 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $15,490 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 12 | $14,932 |
| Emgality PenGalcanezumab-Gnlm | 18 | $13,434 |
| Nurtec OdtRimegepant Sulfate | 13 | $13,196 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $12,584 |
| JanuviaSitagliptin Phosphate | 23 | $12,347 |
| FarxigaDapagliflozin Propanediol | 14 | $12,216 |
| LinzessLinaclotide | 15 | $9,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $298 | $88,67566 claims |
| GSKTrelegy Ellipta | $317 | $83,16197 claims |
| Lilly USA, LLCMounjaro, Trulicity | $121 | $64,23363 claims |
| PfizerEliquis, Nurtec Odt | $147 | $34,35235 claims |
| Boehringer IngelheimJardiance | $45 | $33,31239 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Bevespi Aerosphere | $177 | $32,34747 claims |
| AbbVieVraylar, Linzess | $762 | $26,58927 claims |
| MerckJanuvia | $15 | $12,34723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,404 physician assistant providers in Tennessee.
Other physician assistant in Newport
- Lindsey NixKnoxville$576K
- Anna KerseySavannah$399K
- Jason HenryNashville$329K
- Brie ChandlerNashville$317K
- Loree EasleyBartlett$209K
- Katherine RunyanKnoxville$156K
- John KramerNashville$125K
- Robert LaughertyAlcoa$122K
- Elisabeth BennettNashville$109K
- Whitney GatewoodMemphis$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.